Anaveon presents updated data from the Phase I/II study of ANV419 during the ESMO Congress 2022 - ANV419 is well-tolerated at high doses and demonstrates notable safety with strong pharmacodynamic effects and excellent IL-2Rbg selectivity – - A Phase II program of ANV419 has been initiated in...

Anaveon to raise CHF 110 million in oversubscribed Series B financing - Leading international syndicate led by Forbion and corner-stoned by founding investor Syncona- Confirms depth of support for Anaveon’s approach to developing engineered cytokines in multiple...